Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Placebo-controlled, Randomized, Double-blind, Sponsor-unblinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of Staphylococcus Aureus 4-antigen Vaccine (sa4ag) In Japanese Adults

NCT02492958 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02492958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02492958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Placebo-controlled, Randomized, Double-blind, Sponsor-unblinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of Staphylococcus Aureus 4-antigen Vaccine (sa4ag) In Japanese Adults
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
September 30, 2016
Enrollment
136 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

staphylococcal infections